Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Bristol-Myers Squibb
Related studies linked through entity extraction aliases.
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Evaluate the Effect of Fluconazole, Bupropion, or Itraconazole on the Drug Levels and Safety of BMS-986235
- Status
- WITHDRAWN
- Phase
- PHASE1
Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases
- Status
- COMPLETED
- Phase
- PHASE1
Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of JNJ-70033093 in Healthy Participants
- Status
- COMPLETED
- Phase
- PHASE1
Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986331 in Healthy Participants
- Status
- COMPLETED
- Phase
- PHASE1
Neoadjuvant Immunotherapy in Brain Metastases
- Status
- TERMINATED
- Phase
- PHASE2
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
- Status
- TERMINATED
- Phase
- PHASE3
COVID-19 Ozanimod Intervention Study
- Status
- TERMINATED
- Phase
- PHASE2
Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology
- Status
- COMPLETED
- Phase
- N/A
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis
- Status
- RECRUITING
- Phase
- PHASE2
Safety and Efficacy of Therapeutic Anticoagulation on Clinical Outcomes in Hospitalized Patients With COVID-19
- Status
- UNKNOWN
- Phase
- PHASE2
Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
- Status
- TERMINATED
- Phase
- PHASE2